Literature DB >> 15603089

Emerging technology for at-risk chronically ill veterans.

Mary Huddleston1, Rita Kobb.   

Abstract

Patients are exposed to iatrogenic injury when hospitalized. In the Tech Care Coordination Program, older veterans with chronic diseases and high healthcare utilization were followed with an in-home technology device, the Health Buddy, and risk management software. Program staff could identify at-risk patients based on their responses to a series of questions about symptoms, behavior, and knowledge. Patients followed in the program for at least 6 months experienced a 45% decrease in hospital admissions, 67% decrease in nursing home admissions, 54% decrease in emergency room visits, and 38% decrease in pharmacy prescriptions. The patients also demonstrated improved compliance with treatment regimens and both patients and providers reported high levels of program satisfaction.

Entities:  

Mesh:

Year:  2004        PMID: 15603089     DOI: 10.1111/j.1945-1474.2004.tb00528.x

Source DB:  PubMed          Journal:  J Healthc Qual        ISSN: 1062-2551            Impact factor:   1.095


  3 in total

1.  Rates of major depressive disorder and clinical outcomes following traumatic brain injury.

Authors:  Charles H Bombardier; Jesse R Fann; Nancy R Temkin; Peter C Esselman; Jason Barber; Sureyya S Dikmen
Journal:  JAMA       Date:  2010-05-19       Impact factor: 56.272

2.  Using Information and Communication Technology in Home Care for Communication between Patients, Family Members, and Healthcare Professionals: A Systematic Review.

Authors:  Birgitta Lindberg; Carina Nilsson; Daniel Zotterman; Siv Söderberg; Lisa Skär
Journal:  Int J Telemed Appl       Date:  2013-04-10

3.  The association between processes, structures and outcomes of secondary prevention care among VA ischemic heart disease patients.

Authors:  P Michael Ho; Allan V Prochazka; David J Magid; Anne E Sales; Gary K Grunwald; Karl E Hammermeister; John S Rumsfeld
Journal:  BMC Cardiovasc Disord       Date:  2006-02-09       Impact factor: 2.298

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.